24786-52-5

Usage

Uses

Used in Pharmaceutical Development:
5-amino-6-bromo-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one(SALTDATA: FREE) is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure, including the benzimidazole core and the substituents, may offer specific biological activities that can be harnessed for therapeutic purposes.
Used in Research:
In the scientific community, 5-amino-6-bromo-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one(SALTDATA: FREE) serves as a research tool to explore the structure-activity relationships of benzimidazole derivatives. It can be used to investigate the effects of different functional groups on the biological activity and pharmacokinetic properties of these compounds.
Used in Chemical Synthesis:
5-amino-6-bromo-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one(SALTDATA: FREE) can be employed as a starting material or building block in the synthesis of more complex organic molecules. Its reactive functional groups, such as the amino and bromine atoms, can be further modified to create a variety of novel compounds with potential applications in various fields.
It is important to handle 5-amino-6-bromo-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one(SALTDATA: FREE) with care, as it may pose health and environmental risks. Proper safety measures and disposal methods should be followed to minimize any potential hazards associated with this chemical compound.

InChI:InChI=1/C9H10BrN3O/c1-12-7-3-5(10)6(11)4-8(7)13(2)9(12)14/h3-4H,11H2,1-2H3

Upstream product

• 43027-50-5 1,3-dimethyl-5-nitro-1,3-dihydro-2H-benzimidazol-2-one 
• 53439-88-6 5-amino-1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one 

Relevant academic research and scientific papers

BROMODOMAIN INHIBITORS FOR TREATING DISEASE

Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

The bromodomain containing proteins TRIM24 (tripartite motif containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are involved in the epigenetic regulation of gene expression and have been implicated in human cancer. Overexpression of TRIM24 correlates with poor patient prognosis, and BRPF1 is a scaffolding protein required for the assembly of histone acetyltransferase complexes, where the gene of MOZ (monocytic leukemia zinc finger protein) was first identified as a recurrent fusion partner in leukemia patients (8p11 chromosomal rearrangements). Here, we present the structure guided development of a series of N,N-dimethylbenzimidazolone bromodomain inhibitors through the iterative use of X-ray cocrystal structures. A unique binding mode enabled the design of a potent and selective inhibitor 8i (IACS-9571) with low nanomolar affinities for TRIM24 and BRPF1 (ITC Kd = 31 nM and ITC Kd = 14 nM, respectively). With its excellent cellular potency (EC50 = 50 nM) and favorable pharmacokinetic properties (F = 29%), 8i is a high-quality chemical probe for the evaluation of TRIM24 and/or BRPF1 bromodomain function in vitro and in vivo.